EditorialKommentar
Oral Fosfomycin for Pyelonephritis: Re-examining the Pooled Evidence
Clinical Infectious Diseases · 14.11.2026
DOI: 10.1093/cid/ciag710 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Infectious Diseases, online erschienen am 14.11.2026. Verfasst von Recep Balik. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Haydarpaşa Numune Training and Research Hospital, İstanbul, Türkiye.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Haydarpaşa Numune Training and Research Hospital, İstanbul, Türkiye.
ORCID-Profile: Recep Balik
Zitieren
APA
Balik, R. (2026). Oral Fosfomycin for Pyelonephritis: Re-examining the Pooled Evidence. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag710
Vancouver
Balik R. Oral Fosfomycin for Pyelonephritis: Re-examining the Pooled Evidence. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag710
BibTeX
@article{Balik2026,
author = {Balik, Recep},
title = {Oral Fosfomycin for Pyelonephritis: Re-examining the Pooled Evidence},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag710}
}
EUVIMED